Metropolitan Life Insurance Company (MetLife)’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,846	Closed	-$36.4K	–	1125
2024 Q1	$36.4K	Hold	1,846	–	–	﹤0.01%	1561
2023 Q4	$32.4K	Hold	1,846	–	–	﹤0.01%	1667
2023 Q3	$32.1K	Hold	1,846	–	–	﹤0.01%	1644
2023 Q2	$26K	Buy	+1,846	New	+$24.7K	﹤0.01%	1788
2023 Q1	–	Sell	-1,846	Closed	-$27.7K	–	2395
2022 Q4	$27.7K	Hold	1,846	–	–	﹤0.01%	1832
2022 Q3	$23.7K	Hold	1,846	–	–	﹤0.01%	1936
2022 Q2	$17.9K	Hold	1,846	–	–	﹤0.01%	2093
2022 Q1	$18.3K	Sell	1,846 -2,907	-61%	-$30.8K	﹤0.01%	2133
2021 Q4	$55.9K	Buy	4,753 +180	+4%	+$2.21K	﹤0.01%	2690
2021 Q3	$52.1K	Buy	+4,573	New	+$59.6K	﹤0.01%	2755
2021 Q2	–	Sell	-7,548	Closed	-$140K	–	2795
2021 Q1	$140K	Sell	7,548 -890	-11%	-$18.2K	﹤0.01%	2254
2020 Q4	$149K	Hold	8,438	–	–	﹤0.01%	2136
2020 Q3	$129K	Buy	8,438 +2,221	+36%	+$41.7K	﹤0.01%	2071
2020 Q2	$158K	Buy	6,217 +1,225	+25%	+$25.6K	﹤0.01%	1963
2020 Q1	$77.3K	Buy	+4,992	New	+$78.1K	﹤0.01%	2195

Other funds holding KNSA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KNSA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2024, closing a stake of 1,846 shares — an estimated $36.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KNSA in Q1 2020 and held it in 15 quarters. The position peaked at $158K in Q2 2020. 132 funds tracked by Wall St. Rank hold KNSA as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Kiniksa Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,846 Kiniksa Pharmaceuticals shares in Q2 2024, an estimated $36.4K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Kiniksa Pharmaceuticals in Q1 2020 and held it in 15 quarters.
Metropolitan Life Insurance Company (MetLife)'s Kiniksa Pharmaceuticals position peaked at $158K in Q2 2020.
132 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.